TDMS Study 05069-07 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE
NTP Experiment-Test: 05069-07 Report: PEIRPT03
Study Type: CHRONIC Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
CORE STUDY
Facility: TSI Mason Research
Chemical CAS #: 147-47-7
Lock Date: 08/05/92
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 002 0 MG/KG
Include 004 3.6 MG/KG
Include 006 6.0 MG/KG
Include 008 10.0 MG/KG
Include 001 0 MG/KG
Include 003 3.6 MG/KG
Include 005 6.0 MG/KG
Include 007 10.0 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Moribund Sacrifice 6 7 7 6
Natural Death 10 3 3 4
Accidently Killed 1
Survivors
Terminal Sacrifice 34 40 40 40
Animals Examined Microscopically 50 50 51 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (47) (48) (45)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic 1 (2%)
Intestine Large, Colon (49) (50) (51) (49)
Congestion 1 (2%)
Intestine Large, Cecum (49) (49) (50) (49)
Congestion 1 (2%)
Inflammation, Granulomatous 1 (2%)
Perforation 1 (2%)
Intestine Small, Jejunum (44) (47) (51) (49)
Amyloid Deposition 1 (2%)
Congestion 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Intestine Small, Ileum (45) (49) (49) (48)
Congestion 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Liver (50) (50) (51) (50)
Angiectasis 1 (2%) 3 (6%) 1 (2%)
Clear Cell Focus 9 (18%) 7 (14%) 5 (10%) 5 (10%)
Congestion 1 (2%)
Eosinophilic Focus 17 (34%) 20 (40%) 19 (37%) 22 (44%)
Hematopoietic Cell Proliferation 1 (2%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (2%)
Mineralization 1 (2%)
Mixed Cell Focus 3 (6%) 2 (4%) 2 (4%) 6 (12%)
Necrosis 3 (6%) 2 (4%) 1 (2%)
Thrombosis 1 (2%)
Vacuolization Cytoplasmic 2 (4%) 4 (8%) 2 (4%)
Centrilobular, Necrosis 2 (4%) 1 (2%)
Mesentery (9) (8) (11) (8)
Hyperplasia, Lymphoid 1 (9%)
Fat, Inflammation, Chronic Active 1 (13%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fat, Necrosis 6 (67%) 7 (88%) 9 (82%) 7 (88%)
Pancreas (50) (50) (51) (50)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic 3 (6%)
Necrosis 1 (2%)
Acinus, Atrophy 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Acinus, Hyperplasia 1 (2%) 1 (2%)
Duct, Cyst 1 (2%) 2 (4%)
Salivary Glands (50) (49) (51) (50)
Fibrosis 1 (2%) 1 (2%)
Acinus, Atrophy 1 (2%) 1 (2%) 1 (2%) 4 (8%)
Stomach, Forestomach (50) (50) (51) (50)
Hyperplasia, Squamous 2 (4%) 2 (4%) 4 (8%) 2 (4%)
Infiltration Cellular, Eosinophil 1 (2%)
Ulcer 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (51) (50)
Erosion 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
Mineralization 1 (2%) 4 (8%) 1 (2%) 2 (4%)
Ulcer 1 (2%)
Glands, Cyst 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (51) (50)
Cardiomyopathy 6 (12%) 6 (12%) 11 (22%) 5 (10%)
Inflammation, Chronic Active 1 (2%)
Mineralization 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (49) (51) (50)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 1 (2%) 2 (4%)
Hypertrophy 1 (2%)
Capsule, Hyperplasia 48 (100%) 49 (100%) 50 (98%) 50 (100%)
Adrenal Medulla (48) (49) (49) (50)
Hyperplasia 4 (8%) 3 (6%) 2 (4%)
Islets, Pancreatic (49) (50) (51) (50)
Hyperplasia 30 (61%) 26 (52%) 32 (63%) 31 (62%)
Parathyroid Gland (40) (44) (45) (42)
Cyst 1 (3%) 1 (2%)
Pituitary Gland (44) (48) (47) (45)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Pars Distalis, Angiectasis 1 (2%) 2 (4%) 4 (9%)
Pars Distalis, Hyperplasia 22 (50%) 23 (48%) 17 (36%) 20 (44%)
Rathke's Cleft, Hemorrhage 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Cyst 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Fibrosis 1 (2%)
Inflammation, Chronic 1 (2%)
C-Cell, Hyperplasia 1 (2%)
Follicle, Hypertrophy 1 (2%)
Follicular Cell, Hyperplasia 20 (41%) 25 (50%) 25 (50%) 21 (42%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48) (50) (50) (50)
Inflammation, Acute 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Pigmentation 1 (2%) 2 (4%) 1 (2%)
Arteriole, Inflammation, Chronic 1 (2%)
Ovary (50) (49) (50) (49)
Angiectasis 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Atrophy 1 (2%)
Cyst 14 (28%) 11 (22%) 10 (20%) 14 (29%)
Hemorrhage 3 (6%) 1 (2%) 2 (4%) 2 (4%)
Infiltration Cellular, Lymphocyte 1 (2%)
Inflammation, Granulomatous 1 (2%)
Periovarian Tissue, Inflammation, Chronic
Active 1 (2%)
Periovarian Tissue, Necrosis 3 (6%) 1 (2%) 1 (2%) 1 (2%)
Uterus (50) (50) (51) (50)
Amyloid Deposition 1 (2%)
Angiectasis 3 (6%) 2 (4%)
Dilatation 6 (12%) 3 (6%) 1 (2%) 8 (16%)
Hemorrhage 1 (2%) 1 (2%) 1 (2%)
Hyperplasia, Cystic 42 (84%) 45 (90%) 44 (86%) 47 (94%)
Inflammation, Acute 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (51) (50)
Myelofibrosis 11 (22%) 16 (32%) 15 (29%) 13 (26%)
Lymph Node (8) (4) (5) (3)
Iliac, Angiectasis 1 (13%)
Iliac, Hemorrhage 1 (33%)
Pancreatic, Hyperplasia, Lymphoid 1 (25%)
Lymph Node, Mandibular (50) (49) (51) (50)
Ectasia 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 1 (2%)
Infiltration Cellular, Plasma Cell 1 (2%)
Lymph Node, Mesenteric (47) (48) (51) (50)
Angiectasis 2 (4%) 3 (6%)
Ectasia 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 1 (2%)
Infiltration Cellular, Plasma Cell 1 (2%)
Spleen (50) (50) (51) (50)
Angiectasis 1 (2%)
Hematopoietic Cell Proliferation 15 (30%) 11 (22%) 13 (25%) 15 (30%)
Hyperplasia, Lymphoid 4 (8%) 9 (18%) 3 (6%) 8 (16%)
Lymphoid Follicle, Atrophy 1 (2%)
Thymus (45) (46) (48) (49)
Angiectasis 1 (2%)
Cyst 3 (6%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50) (49)
Galactocele 1 (2%)
Skin (50) (50) (51) (50)
Acanthosis 1 (2%)
Inflammation, Chronic 1 (2%)
Skin, Site of Application, Acanthosis 1 (2%) 1 (2%)
Skin, Site of Application, Hyperplasia, Mast
Cell 1 (2%)
Subcutaneous Tissue, Angiectasis 1 (2%)
Subcutaneous Tissue, Congestion 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic 1 (2%) 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (1) (1) (1)
Inflammation, Chronic Active 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (51) (50)
Hydrocephalus 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Thalamus, Mineralization 21 (42%) 18 (36%) 14 (27%) 17 (34%)
Peripheral Nerve (1) (2) (1)
Demyelination 1 (100%) 2 (100%) 1 (100%)
Spinal Cord (1) (2) (1)
Demyelination 1 (100%) 2 (100%)
Axon, Degeneration 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (51) (50)
Hemorrhage 3 (6%) 3 (6%) 2 (4%) 7 (14%)
Infiltration Cellular, Histiocyte 2 (4%) 1 (2%) 3 (6%) 3 (6%)
Inflammation, Chronic 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (4%) 1 (2%)
Bronchiole, Degeneration, Hyaline 1 (2%)
Serosa, Inflammation, Chronic 1 (2%)
Nose (50) (49) (51) (50)
Angiectasis 1 (2%)
Exudate 2 (4%) 1 (2%) 2 (4%)
Foreign Body 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%)
Glands, Inflammation, Acute 17 (34%) 15 (31%) 20 (39%) 12 (24%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (51) (50)
Casts Protein 1 (2%)
Cyst 1 (2%) 1 (2%)
Hydronephrosis 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Hyperplasia, Lymphoid 2 (4%)
Infiltration Cellular, Lymphocyte 2 (4%)
Inflammation, Acute 1 (2%)
Metaplasia, Osseous 1 (2%) 1 (2%)
Nephropathy, Chronic 33 (66%) 32 (64%) 37 (73%) 36 (72%)
Pigmentation 2 (4%) 1 (2%)
Renal Tubule, Atrophy 1 (2%)
Renal Tubule, Degeneration, Hyaline 2 (4%) 1 (2%)
Renal Tubule, Necrosis 1 (2%) 1 (2%) 2 (4%)
Urinary Bladder (50) (50) (51) (49)
Hyperplasia, Lymphoid 1 (2%)
Arteriole, Inflammation, Chronic 1 (2%)
Serosa, Inflammation, Acute 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Natural Death 6 8 2 10
Moribund Sacrifice 5 4 7 3
Accidently Killed 1
Survivors
Terminal Sacrifice 39 37 41 37
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (46) (46) (47) (41)
Hyperplasia 1 (2%)
Intestine Large, Rectum (48) (49) (50) (49)
Inflammation, Acute 1 (2%)
Necrosis 1 (2%)
Intestine Large, Cecum (48) (50) (50) (46)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Intestine Small, Ileum (45) (46) (47) (44)
Inflammation, Chronic Active 1 (2%)
Necrosis 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis 2 (4%) 1 (2%)
Basophilic Focus 1 (2%) 3 (6%)
Clear Cell Focus 24 (48%) 21 (42%) 20 (40%) 28 (56%)
Congestion 3 (6%) 1 (2%) 2 (4%)
Cyst 1 (2%) 1 (2%)
Eosinophilic Focus 20 (40%) 21 (42%) 22 (44%) 10 (20%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hyperplasia 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Mixed Cell Focus 9 (18%) 9 (18%) 12 (24%) 16 (32%)
Necrosis 2 (4%) 4 (8%) 2 (4%) 3 (6%)
Vacuolization Cytoplasmic 1 (2%) 2 (4%) 1 (2%)
Mesentery (1) (2) (3)
Inflammation, Granulomatous 1 (50%)
Fat, Necrosis 1 (100%) 1 (33%)
Pancreas (49) (49) (50) (49)
Inflammation, Chronic 1 (2%) 1 (2%) 2 (4%)
Inflammation, Chronic Active 1 (2%)
Acinus, Atrophy 8 (16%) 4 (8%) 5 (10%) 5 (10%)
Artery, Inflammation, Chronic 1 (2%)
Duct, Cyst 1 (2%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Stomach, Forestomach (49) (50) (50) (48)
Hyperplasia, Squamous 4 (8%) 1 (2%) 1 (2%) 1 (2%)
Ulcer 2 (4%)
Stomach, Glandular (48) (50) (50) (48)
Erosion 1 (2%) 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Infiltration Cellular, Eosinophil 1 (2%)
Inflammation, Chronic 1 (2%)
Mineralization 1 (2%)
Tooth (21) (16) (26) (13)
Dysplasia 21 (100%) 15 (94%) 26 (100%) 13 (100%)
Inflammation, Chronic Active 1 (6%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 2 (4%) 7 (14%) 7 (14%) 4 (8%)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%)
Mineralization 1 (2%)
Valve, Inflammation, Acute 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (49) (50)
Angiectasis 1 (2%)
Cytoplasmic Alteration 1 (2%)
Hyperplasia 6 (12%) 8 (16%) 6 (12%) 4 (8%)
Hypertrophy 23 (47%) 19 (39%) 16 (33%) 17 (34%)
Vacuolization Cytoplasmic 1 (2%)
Capsule, Hyperplasia 43 (88%) 43 (88%) 42 (86%) 38 (76%)
Adrenal Medulla (48) (49) (49) (50)
Hyperplasia 2 (4%) 1 (2%) 1 (2%)
Islets, Pancreatic (49) (49) (50) (49)
Hyperplasia 47 (96%) 45 (92%) 48 (96%) 47 (96%)
Pituitary Gland (45) (43) (40) (46)
Pars Distalis, Cyst 2 (4%) 2 (5%) 2 (5%) 3 (7%)
Pars Distalis, Hyperplasia 1 (2%) 1 (3%)
Thyroid Gland (49) (50) (50) (50)
Inflammation, Chronic 1 (2%) 1 (2%)
Follicle, Dilatation 2 (4%) 1 (2%)
Follicular Cell, Hyperplasia 8 (16%) 3 (6%) 9 (18%) 6 (12%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Granuloma Sperm 1 (2%) 2 (4%) 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Granulomatous 1 (2%)
Spermatocele 2 (4%) 1 (2%) 2 (4%)
Penis (1)
Concretion 1 (100%)
Inflammation, Chronic Active 1 (100%)
Preputial Gland (48) (50) (50) (50)
Dilatation 14 (29%) 11 (22%) 17 (34%) 16 (32%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 14 (29%) 18 (36%) 17 (34%) 14 (28%)
Inflammation, Chronic Active 5 (10%) 2 (4%) 2 (4%) 4 (8%)
Metaplasia, Squamous 1 (2%)
Prostate (49) (50) (50) (50)
Concretion 1 (2%)
Cyst 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Inflammation, Chronic Active 1 (2%)
Seminal Vesicle (49) (50) (50) (50)
Fibrosis 1 (2%)
Hyperplasia 2 (4%)
Hypertrophy 8 (16%)
Inflammation, Chronic 1 (2%) 1 (2%) 2 (4%)
Testes (49) (50) (50) (50)
Giant Cell 1 (2%)
Granuloma Sperm 1 (2%)
Seminiferous Tubule, Degeneration 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50) (49)
Granuloma 1 (2%)
Hyperplasia, Mast Cell 1 (2%)
Myelofibrosis 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mandibular (49) (48) (49) (48)
Angiectasis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Lymph Node, Mesenteric (48) (47) (50) (47)
Angiectasis 8 (17%) 2 (4%) 1 (2%) 8 (17%)
Hemorrhage 1 (2%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
Spleen (48) (49) (49) (50)
Angiectasis 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 7 (15%) 5 (10%) 5 (10%) 8 (16%)
Hyperplasia, Lymphoid 1 (2%) 4 (8%)
Lymphoid Follicle, Atrophy 1 (2%)
Red Pulp, Atrophy 1 (2%) 1 (2%)
Thymus (39) (42) (46) (40)
Atrophy 1 (3%)
Cyst 3 (8%) 1 (2%) 1 (3%)
Ectopic Parathyroid Gland 1 (2%) 1 (2%)
Hyperplasia 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Acanthosis 1 (2%)
Hyperkeratosis 1 (2%) 1 (2%)
Skin, Site of Application, Acanthosis 1 (2%) 1 (2%) 1 (2%)
Skin, Site of Application, Hyperkeratosis 1 (2%)
Skin, Site of Application, Ulcer 1 (2%)
Subcutaneous Tissue, Abscess 1 (2%)
Subcutaneous Tissue, Edema 1 (2%)
Subcutaneous Tissue, Granuloma 1 (2%)
Subcutaneous Tissue, Hemorrhage 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic 2 (4%)
Subcutaneous Tissue, Inflammation, Chronic
Active 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50) (49)
Vertebra, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Hemorrhage 1 (2%)
Thalamus, Mineralization 24 (48%) 24 (48%) 23 (46%) 18 (36%)
Spinal Cord (1)
Demyelination 1 (100%)
Gray Matter, Necrosis 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Congestion 1 (2%)
Hemorrhage 4 (8%) 5 (10%) 4 (8%) 4 (8%)
Infiltration Cellular, Histiocyte 8 (16%) 3 (6%) 7 (14%) 6 (12%)
Inflammation, Chronic 2 (4%)
Metaplasia, Osseous 1 (2%) 1 (2%)
Pigmentation 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (6%) 4 (8%) 3 (6%) 6 (12%)
Nose (50) (50) (50) (50)
Exudate 1 (2%) 2 (4%) 8 (16%) 3 (6%)
Foreign Body 1 (2%)
Inflammation, Acute 1 (2%) 2 (4%) 5 (10%)
Polyp, Inflammatory 1 (2%) 1 (2%) 2 (4%)
Glands, Inflammation, Acute 22 (44%) 12 (24%) 11 (22%) 13 (26%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1)
Atrophy 1 (100%)
Lens, Cataract 1 (100%)
Harderian Gland (4) (5) (5) (3)
Cyst 1 (25%)
Inflammation, Granulomatous 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Cyst 10 (20%) 8 (16%) 8 (16%) 8 (16%)
Granuloma 1 (2%)
Hydronephrosis 3 (6%) 1 (2%)
Infarct 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Inflammation, Acute 1 (2%)
Metaplasia, Osseous 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 15:36:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Nephropathy, Acute 1 (2%)
Nephropathy, Chronic 45 (90%) 43 (86%) 50 (100%) 46 (92%)
Pigmentation 1 (2%)
Cortex, Mineralization 35 (70%) 40 (80%) 45 (90%) 36 (72%)
Renal Tubule, Degeneration, Hyaline 1 (2%) 1 (2%)
Renal Tubule, Hyperplasia 1 (2%)
Urinary Bladder (49) (50) (50) (46)
Calculus Gross Observation 1 (2%) 2 (4%) 1 (2%)
Calculus Micro Observation Only 3 (6%) 2 (4%) 6 (12%)
Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------